RNAi技術市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、用途別、エンドユーザー別、地域別、競合別、2020-2030年

世界のRNAi技術市場は、2024年に11億9,000万米ドルと評価され、2030年には21億4,000万米ドルに達し、予測期間中にCAGR 10.28％で拡大すると予測されています。

RNA干渉（RNAi）は、低分子RNAを通じて標的遺伝子のサイレンシングを可能にし、バイオテクノロジーと製薬分野における変革ツールとして登場しました。このメカニズムは、遺伝子制御と治療革新の状況を再形成し、医薬品開発、遺伝子治療、農業、分子研究に応用されています。疾患関連遺伝子を選択的に阻害する能力を持つRNAiは、がん、遺伝性疾患、ウイルス感染などの複雑な病態を治療するための薬剤パイプラインに組み込まれることが多くなっています。製薬会社は、その高い精度、適応性、個別化治療開発の可能性から、RNAiベースのアプローチを優先しています。送達システムの継続的な進歩と、RNAi治療薬および診断薬への投資の増加が相まって、2030年までの市場の堅調な拡大が見込まれています。

市場促進要因

RNAiベースの治療薬に対する需要の高まり

主な市場課題

オフターゲット効果

主な市場動向

精密医療と個別化治療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のRNAi技術市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（マイクロRNA、低分子干渉RNA、その他）
  • 用途別（治療タイプ、治療法、ドラッグデリバリー、農業、その他）
  • エンドユーザー別（調査・学術機関、診断機関、その他）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米のRNAi技術市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のRNAi技術市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のRNAi技術市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のRNAi技術市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのRNAi技術市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のRNAi技術市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Alnylam Pharmaceuticals, Inc
• Ionis Pharmaceuticals, Inc.
• Atalanta Therapeutics
• Phio Pharmaceuticals
• Benitec Biopharma
• Novartis AG
• AstraZeneca
• Silence Therapeutics
• Arbutus Biopharma
• Sylentis S.A.

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global RNAi Technology Market was valued at USD 1.19 billion in 2024 and is projected to reach USD 2.14 billion by 2030, expanding at a CAGR of 10.28% during the forecast period. RNA interference (RNAi) has emerged as a transformative tool in the biotechnology and pharmaceutical sectors, enabling targeted gene silencing through small RNA molecules. This mechanism has reshaped the landscape of gene regulation and therapeutic innovation, finding applications across drug development, gene therapy, agriculture, and molecular research. With its ability to selectively inhibit disease-related genes, RNAi is increasingly being integrated into drug pipelines for treating complex conditions such as cancer, genetic disorders, and viral infections. Pharmaceutical companies are prioritizing RNAi-based approaches due to their high precision, adaptability, and potential for developing personalized treatments. The continuous advancements in delivery systems, coupled with growing investments in RNAi therapeutics and diagnostics, are expected to drive robust market expansion through 2030.

Key Market Drivers

Growing Demand for RNAi-based Therapeutics

The rising demand for RNAi-based therapeutics plays a critical role in propelling the growth of the global RNAi technology market. RNAi enables highly targeted treatment by silencing genes that contribute to the progression of chronic and genetic diseases, such as certain cancers, viral infections, and neurodegenerative conditions. As the global prevalence of such disorders continues to rise, there is a growing need for precise and less invasive treatment options. RNAi-based drugs support a personalized medicine approach, tailoring therapies based on individual genetic profiles and minimizing off-target effects. The successful commercialization of RNAi therapies, such as Onpattro, has strengthened confidence in the clinical viability of these treatments, encouraging more companies to invest in research and development. Furthermore, RNAi's utility in functional genomics and target validation makes it a valuable tool in drug discovery, reinforcing its expanding role across both therapeutic and research domains.

Key Market Challenges

Off-Target Effects

Off-target gene silencing presents a major obstacle to the widespread adoption of RNAi technology. Although RNAi is known for its precision, unintended interactions with non-target genes can lead to undesired cellular responses, including toxicity or immune reactions. These safety concerns require extensive preclinical and clinical validation, increasing development time and costs. Designing RNAi molecules with high specificity remains a complex task, particularly when targeting genes in complex biological systems. Off-target effects not only compromise therapeutic outcomes but also affect research accuracy in functional genomics. Addressing this challenge involves improving RNA sequence design, refining delivery mechanisms, and enhancing regulatory oversight to ensure the safe application of RNAi in both clinical and research settings.

Key Market Trends

Precision Medicine and Personalized Therapies

The integration of RNAi technology into precision medicine is a significant trend shaping the future of the healthcare industry. As personalized therapies become increasingly important, RNAi's ability to silence specific genetic mutations makes it an ideal platform for individualized treatment strategies. In oncology, for instance, RNAi-based therapies are being developed to target genetic mutations unique to different tumor types, offering greater efficacy and reduced side effects compared to conventional therapies. This alignment with personalized medicine is also driving partnerships and R&D efforts focused on developing tailored RNAi-based solutions. By enabling gene-specific modulation, RNAi supports the broader shift toward customized, data-driven healthcare approaches.

Key Market Players

• Alnylam Pharmaceuticals, Inc
• Ionis Pharmaceuticals, Inc.
• Atalanta Therapeutics
• Phio Pharmaceuticals
• Benitec Biopharma
• Novartis AG
• AstraZeneca
• Silence Therapeutics
• Arbutus Biopharma
• Sylentis S.A.

Report Scope:

In this report, the Global RNAi Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNAi Technology Market, By Type:

• Micro RNA
• Small interfering RNA
• Others

RNAi Technology Market, By Application:

• Treatment Type
• Therapeutics
• Drug Delivery
• Agriculture
• Others

RNAi Technology Market, By End User:

• Research and Academic Laboratories
• Diagnostic Laboratories
• Others

RNAi Technology Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNAi Technology Market.

Available Customizations:

Global RNAi Technology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global RNAi Technology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Micro RNA, Small interfering RNA, Others)
  • 5.2.2. By Application (Treatment Type, Therapeutics, Drug Delivery, Agriculture, Others)
  • 5.2.3. By End User (Research and Academic Laboratories, Diagnostic Laboratories, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America RNAi Technology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States RNAi Technology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Mexico RNAi Technology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Canada RNAi Technology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe RNAi Technology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France RNAi Technology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany RNAi Technology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom RNAi Technology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy RNAi Technology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain RNAi Technology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific RNAi Technology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China RNAi Technology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India RNAi Technology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. South Korea RNAi Technology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. Japan RNAi Technology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia RNAi Technology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America RNAi Technology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil RNAi Technology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina RNAi Technology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia RNAi Technology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa RNAi Technology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa RNAi Technology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia RNAi Technology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE RNAi Technology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global RNAi Technology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Alnylam Pharmaceuticals, Inc
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Ionis Pharmaceuticals, Inc.
• 15.3. Atalanta Therapeutics
• 15.4. Phio Pharmaceuticals
• 15.5. Benitec Biopharma
• 15.6. Novartis AG
• 15.7. AstraZeneca
• 15.8. Silence Therapeutics
• 15.9. Arbutus Biopharma
• 15.10. Sylentis S.A.

16. Strategic Recommendations

17. About Us & Disclaimer